National health insurer Centene is pulling out of Hawaii's Medicaid market, leaving 24,000 members in need of a new plan. For ...
Rothschild & Co Redburn è positivo sul titolo e consiglia Buy. Revisione al rialzo del prezzo obiettivo che passa da 251 USD ...
Quest Diagnostics is investigating unauthorized access to its Quanum Lab Services Manager after certain patient records were ...
Australia's 2026 cyber threat report reveals a 20% rise in security incidents and an 80% surge in warnings as AI accelerates ...
Zacks Investment Research on MSN
Waters & Labcorp expand access to FDA-approved HPV screening tests
Waters WAT recently announced a partnership with Labcorp Holdings Inc. LH to expand access to the FDA-approved BD Onclarity ...
Zacks Investment Research on MSN
Why Quest Diagnostics (DGX) is a top value stock for the long term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...
Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $257.57, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results